105 related articles for article (PubMed ID: 30935843)
1. The effect of a treatment delay on outcome in metastatic renal cell carcinoma.
Iacovelli R; Galli L; De Giorgi U; Porta C; Nolè F; Zucali P; Sabbatini R; Mosca A; Atzori F; Santini D; Facchini G; Fornarini G; Buti S; Massari F; Masini C; Ricotta R; Biasco E; Lolli C; Gri N; Verri E; Miggiano C; Vitale MG; Tortora G
Urol Oncol; 2019 Aug; 37(8):529.e1-529.e7. PubMed ID: 30935843
[TBL] [Abstract][Full Text] [Related]
2. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Heng DY; Wells JC; Rini BI; Beuselinck B; Lee JL; Knox JJ; Bjarnason GA; Pal SK; Kollmannsberger CK; Yuasa T; Srinivas S; Donskov F; Bamias A; Wood LA; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Kim JJ; Choueiri TK
Eur Urol; 2014 Oct; 66(4):704-10. PubMed ID: 24931622
[TBL] [Abstract][Full Text] [Related]
3. Normalization of C-reactive protein levels following cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors is associated with improved overall survival.
Teishima J; Ohara S; Shinmei S; Inoue S; Hayashi T; Mochizuki H; Mita K; Shigeta M; Matsubara A
Urol Oncol; 2018 Jul; 36(7):339.e9-339.e15. PubMed ID: 29773493
[TBL] [Abstract][Full Text] [Related]
4. Association of post-treatment hypoalbuminemia and survival in Chinese patients with metastatic renal cell carcinoma.
Cai W; Zhang J; Chen Y; Kong W; Huang Y; Huang J; Zhou L
Chin J Cancer; 2017 May; 36(1):47. PubMed ID: 28521783
[TBL] [Abstract][Full Text] [Related]
5. Clinical Impact of Pancreatic Metastases from Renal Cell Carcinoma: A Multicenter Retrospective Analysis.
Grassi P; Doucet L; Giglione P; Grünwald V; Melichar B; Galli L; De Giorgi U; Sabbatini R; Ortega C; Santoni M; Bamias A; Verzoni E; Derosa L; Studentova H; Pacifici M; Coppa J; Mazzaferro V; de Braud F; Porta C; Escudier B; Procopio G
PLoS One; 2016; 11(4):e0151662. PubMed ID: 27064898
[TBL] [Abstract][Full Text] [Related]
6. Oncological outcomes after cytoreductive nephrectomy for patients with metastatic renal cell carcinoma with inferior vena caval tumor thrombus.
Miyake H; Sugiyama T; Aki R; Matsushita Y; Tamura K; Motoyama D; Ito T; Otsuka A
Int J Clin Oncol; 2018 Jun; 23(3):553-558. PubMed ID: 29332206
[TBL] [Abstract][Full Text] [Related]
7. Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features.
Mathieu R; Pignot G; Ingles A; Crepel M; Bigot P; Bernhard JC; Joly F; Guy L; Ravaud A; Azzouzi AR; Gravis G; Chevreau C; Zini L; Lang H; Pfister C; Lechevallier E; Fais PO; Berger J; Vayleux B; Roupret M; Audenet F; Descazeaud A; Rigaud J; Machiels JP; Staehler M; Salomon L; Ferriere JM; Kleinclauss F; Bensalah K; Patard JJ
Urol Oncol; 2015 Aug; 33(8):339.e9-15. PubMed ID: 26087971
[TBL] [Abstract][Full Text] [Related]
8. The Evolution of Nephrectomy and Patient Characteristics in Metastatic Renal Cell Carcinoma Patients Enrolled Into First-Line Tyrosine Kinase Inhibitors Clinical Trials.
Sella A; Wang K; Sella T
Clin Genitourin Cancer; 2016 Oct; 14(5):415-419. PubMed ID: 27105724
[TBL] [Abstract][Full Text] [Related]
9. Benefit from cytoreductive nephrectomy and the prognostic role of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma.
Day D; Kanjanapan Y; Kwan E; Yip D; Lawrentschuk N; Davis ID; Azad AA; Wong S; Rosenthal M; Gibbs P; Tran B
Intern Med J; 2016 Nov; 46(11):1291-1297. PubMed ID: 27507629
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma treated with first-line sunitinib: a European multiinstitutional study.
Bamias A; Tzannis K; Papatsoris A; Oudard S; Beuselinck B; Escudier B; Liontos M; Elaidi TR; Chrisofos M; Stravodimos K; Anastasiou I; Mitropoulos D; Deliveliotis C; Constantinides C; Dimopoulos MA; Bamia C
Clin Genitourin Cancer; 2014 Oct; 12(5):373-83. PubMed ID: 24819319
[TBL] [Abstract][Full Text] [Related]
11. Sarcopenia as a predictor of overall survival after cytoreductive nephrectomy for metastatic renal cell carcinoma.
Sharma P; Zargar-Shoshtari K; Caracciolo JT; Fishman M; Poch MA; Pow-Sang J; Sexton WJ; Spiess PE
Urol Oncol; 2015 Aug; 33(8):339.e17-23. PubMed ID: 26094169
[TBL] [Abstract][Full Text] [Related]
12. Cytoreductive Nephrectomy for Renal Cell Carcinoma with Venous Tumor Thrombus.
Abel EJ; Spiess PE; Margulis V; Master VA; Mann M; Zargar-Shoshtari K; Borregales LD; Sexton WJ; Patil D; Matin SF; Wood CG; Karam JA
J Urol; 2017 Aug; 198(2):281-288. PubMed ID: 28268170
[TBL] [Abstract][Full Text] [Related]
13. Significance of preoperative prognostic nutrition index as prognostic predictors in patients with metastatic renal cell carcinoma with tyrosine kinase inhibitors as first-line target therapy.
Cai W; Zhong H; Kong W; Dong B; Chen Y; Zhou L; Xue W; Huang Y; Zhang J; Huang J
Int Urol Nephrol; 2017 Nov; 49(11):1955-1963. PubMed ID: 28889323
[TBL] [Abstract][Full Text] [Related]
14. Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology.
Kassouf W; Sanchez-Ortiz R; Tamboli P; Tannir N; Jonasch E; Merchant MM; Matin S; Swanson DA; Wood CG
J Urol; 2007 Nov; 178(5):1896-900. PubMed ID: 17868729
[TBL] [Abstract][Full Text] [Related]
15. Cytoreductive nephrectomy for T4NxM1 renal cell carcinoma: the M.D. Anderson Cancer Center experience.
Kassouf W; Sanchez-Ortiz R; Tamboli P; Jonasch E; Merchant MM; Spiess PE; Wood CG
Urology; 2007 May; 69(5):835-8. PubMed ID: 17482917
[TBL] [Abstract][Full Text] [Related]
16. Hypothyroidism in patients with renal cell carcinoma: blessing or curse?
Schmidinger M; Vogl UM; Bojic M; Lamm W; Heinzl H; Haitel A; Clodi M; Kramer G; Zielinski CC
Cancer; 2011 Feb; 117(3):534-44. PubMed ID: 20845482
[TBL] [Abstract][Full Text] [Related]
17. Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma.
Han KR; Pantuck AJ; Bui MH; Shvarts O; Freitas DG; Zisman A; Leibovich BC; Dorey FJ; Gitlitz BJ; Figlin RA; Belldegrun AS
Urology; 2003 Feb; 61(2):314-9. PubMed ID: 12597937
[TBL] [Abstract][Full Text] [Related]
18. Cytokine therapy response as a selection criterion for cytoreductive nephrectomy in metastatic renal clear-cell carcinoma of intermediate prognosis. Results and conclusions from a combined analysis.
Bex A; Haanen JB; Vyth-Dreese FA; Horenblas S; de Gast GC
Urol Int; 2008; 80(4):367-71. PubMed ID: 18587246
[TBL] [Abstract][Full Text] [Related]
19. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.
Vasselli JR; Yang JC; Linehan WM; White DE; Rosenberg SA; Walther MM
J Urol; 2001 Jul; 166(1):68-72. PubMed ID: 11435825
[TBL] [Abstract][Full Text] [Related]
20. Tyrosine kinase inhibitors in the first-line treatment for metastatic nonclear cell renal carcinoma: A retrospective analysis of a national database.
Poprach A; Rumanova K; Lakomý R; Chloupková R; Stanik M; Pokrivcak T; Kiss I; Slaby O; Studentova H; Melichar B; Juracek J; Fiala O; Kopecky J; Kopeckova K; Zemanova M; Buchler T
Urol Oncol; 2019 Apr; 37(4):294.e1-294.e8. PubMed ID: 30683455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
